Drug intelligence / Profile preview

HMM-910

Development stage: Preclinical
Lead developer: Help Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

HMM-910 is an allogeneic, off-the-shelf cell therapy product derived from induced pluripotent stem cells (iPSCs), developed by Help Therapeutics. It is specifically designed for the treatment of motor system diseases. The therapeutic approach involves the regeneration or replacement of damaged or dysfunctional cells within the motor system to restore functional capacity. As a regenerative cell therapy, HMM-910 does not target a specific molecular pathway but instead addresses the cellular pathology of motor disorders. The product is currently in the concept validation stage of preclinical development.

Beyond the preview

Go deeper on HMM-910.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMM-910.

Explore the full profile